{
    "clinical_study": {
        "@rank": "152985", 
        "arm_group": [
            {
                "arm_group_label": "Sofosbuvir+RBV 12 weeks", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Sofosbuvir+RBV 24 weeks", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a research study to evaluate the safety, tolerability, and anti-viral activity of\n      sofosbuvir with ribavirin in Egyptian adults with genotype 4 hepatitis C infection."
        }, 
        "brief_title": "Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Na\u00efve and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection.", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C Virus", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C", 
                "Virus Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Treatment experienced and na\u00efve subjects\n\n          -  Chronic genotype 4 HCV-infection\n\n          -  Not co-infected with HIV\n\n          -  Screening laboratory values within defined thresholds\n\n          -  Use of highly effective contraception methods\n\n          -  Subject must be able to comply with the dosing instructions for study drug\n             administration and able to complete the study schedule of assessments.\n\n        Exclusion Criteria:\n\n          -  History of any other clinically significant chronic liver disease\n\n          -  Pregnant or nursing female or male with pregnant female partner\n\n          -  History of clinically-significant illness or any other major medical disorder that\n             may interfere with subject treatment, assessment or compliance with the protocol\n\n          -  Excessive alcohol ingestion or significant drug abuse"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01838590", 
            "org_study_id": "GS-US-334-0138"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Sofosbuvir+RBV 12 weeks", 
                    "Sofosbuvir+RBV 24 weeks"
                ], 
                "description": "Sofosbuvir 400 mg tablet administered orally once daily", 
                "intervention_name": "Sofosbuvir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sofosbuvir+RBV 12 weeks", 
                    "Sofosbuvir+RBV 24 weeks"
                ], 
                "description": "Ribavirin (RBV) 200 mb tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and \u2265 75 kg = 1200 mg)", 
                "intervention_name": "RBV", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Anti-Infective Agents", 
                "Ribavirin", 
                "Molecular Mechanisms of Pharmacological Action"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Liver Diseases", 
            "Digestive System Diseases", 
            "Hepatitis, Viral, Human", 
            "Virus Diseases", 
            "Enterovirus Infections", 
            "Picornaviridae Infections", 
            "RNA Virus Infections", 
            "Flaviviridae Infections", 
            "Antiviral Agents", 
            "Anti-Infective Agents", 
            "Therapeutic Uses", 
            "Pharmacologic Actions", 
            "Antimetabolites", 
            "Molecular Mechanisms of Pharmacological Action", 
            "HCV genotype 4 (GT-4)", 
            "HCV", 
            "Sustained Virologic Response", 
            "Direct Acting Antiviral", 
            "Combination Therapy", 
            "GS-7977", 
            "Ribavirin", 
            "Open Label", 
            "Sofosbuvir", 
            "Additional relevant MeSH terms:", 
            "Hepatitis", 
            "Hepatitis, Chronic", 
            "Hepatitis C", 
            "Hepatitis C, Chronic"
        ], 
        "lastchanged_date": "March 14, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Cairo", 
                        "country": "Egypt"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mansoura", 
                        "country": "Egypt"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Egypt"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 3, Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Na\u00efve and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 HCV Infection.", 
        "overall_official": {
            "affiliation": "Gilead Sciences", 
            "last_name": "Kathryn Kersey", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Egypt: Ministry of Health and Population", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "SVR12 is defined as HCV RNA < the lower limit of quantitation (LLOQ) 12 weeks following the last dose of study drug.", 
                "measure": "Proportion of participants with sustained virologic response 12 weeks after discontinuation of treatment (SVR12)", 
                "safety_issue": "No", 
                "time_frame": "Posttreatment Week 12"
            }, 
            {
                "measure": "Any adverse event leading to permanent discontinuation of study drug(s)", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to Week 24"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01838590"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "SVR4 and SVR24 is defined as HCV RNA < the lower limit of quantitation (LLOQ) 4 weeks and 24 weeks following the last dose of study drug, respectively.", 
                "measure": "Proportion of participants with sustained virologic response at 4 and 24 weeks after discontinuation of treatment (SVR4 and SVR24)", 
                "safety_issue": "No", 
                "time_frame": "Posttreatment Weeks 4 and 24"
            }, 
            {
                "description": "On-treatment virologic failure is defined as either:\nBreakthrough: HCV RNA \u2265 LLOQ after having previously had HCV RNA < LLOQ, while on treatment, confirmed with 2 consecutive values (note: second confirmation value can be posttreatment), or last available on-treatment measurement with no subsequent follow up values , or\nRebound: > 1 log10IU/mL increase in HCV RNA from nadir while on treatment, confirmed with 2 consecutive values (note: second confirmation value can be posttreatment), or last available on-treatment measurement with no subsequent follow up values, or\nNonresponse: HCV RNA persistently \u2265 LLOQ through 8 weeks of treatment", 
                "measure": "Proportion of participants with on-treatment virologic failure", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to Week 24"
            }, 
            {
                "description": "Relapse is defined as having HCV RNA \u2265 LLOQ during the posttreatment period having achieved HCV RNA < LLOQ at end of treatment.", 
                "measure": "Proportion of participants with relapse", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to Posttreatment Week 24"
            }
        ], 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}